Back

Change in REVEAL Lite 2 and COMPERA 2.0 risk status in patients with pulmonary arterial hypertension initiating oral treprostinil on dual background therapy: a retrospective chart review

28 August 2022 (17:15 - 17:45)
Organised by:
Congress Presentation Part of: Treatment of pulmonary arterial hypertension: the old and the new Pulmonary Hypertension ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Margaret Sketch

United Therapeutics Corporation, Research Triangle Park (United States of America)

4 More presentations in this session

Presentation thumbnail
Efficacy and dose-response relationship of oral treprostinil in PAH patients on monotherapy or dual background therapy
Doctor J. Barbera (Barcelona, ES)
Abstract Slides
Presentation thumbnail
UNISUS study design: a phase 3 superiority study comparing the efficacy, safety, and tolerability of macitentan 75 mg vs macitentan 10 mg in patients with pulmonary arterial hypertension (PAH)
Professor V. McLaughlin (Ann Arbor, US)
Abstract Slides
Presentation thumbnail
Macitentan for pulmonary arterial hypertension related to repaired congenital heart disease: Real-world UK experience
Doctor A. Constantine (Birmingham, GB)
Abstract Slides
Presentation thumbnail
Human umbilical cord mesenchymal stem cells attenuate experimental pulmonary arterial hypertension
Professor H. Dai (Kunming, CN)
Abstract Slides

Access the full session

Session thumbnail
Treatment of pulmonary arterial hypertension: the old and the new

The Event

Event poster

ESC Congress 2022

28 August 2022 17:15 CET

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources